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ABSTRACT 18 
Simkania negevensis is a Chlamydia-related bacterium discovered in 1993 and represents 19 
the founding member of the Simkaniaceae family within the Chlamydiales order. As 20 
other Chlamydiales, it is an obligate intracellular bacterium characterized by a biphasic 21 
developmental cycle. Its similarities with the pathogenic Chlamydia trachomatis and 22 
Chlamydia pneumoniae make it an interesting bacterium. So far, little is known about its 23 
biology, but S. negevensis harbors various microbiological characteristics of interest 24 
including a strong recruitment of the ER to the Simkania-containing vacuole and the 25 
presence of an intron in the 23S rRNA encoding gene. 26 
Evidence of human exposition has been reported worldwide. However, there is a lack of 27 
robust clinical studies evaluating its implication in human diseases; current data suggest 28 
an association with pneumonia and bronchiolitis making S. negevensis a potential 29 
emerging pathogen. Owing to its fastidious growth requirements, the clinical relevance of 30 
S. negevensis is probably underestimated. In this review, we summarize the current 31 
knowledge on S. negevensis and explore future research challenges.32 
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INTRODUCTION 33 
Several members of the Chlamydiales order are of high clinical importance. For example, 34 
Chlamydia trachomatis is currently the second most common sexually transmitted 35 
disease after human papillomavirus (HPV) (Forhan et al., 2009). This infection can cause 36 
pelvic inflammatory disease (PID) (Bartlett et al., 2013) and lead to infertility as well as 37 
obstetrical complications such as miscarriage and preterm birth (Baud et al., 2011a, 2008; 38 
Gimenes et al., 2014; Pellati et al., 2008). Similarly, Chlamydia pneumoniae commonly 39 
causes bronchitis and pneumonia in children and young adults (Asner et al., 2014; Blasi 40 
et al., 2009; Principi and Esposito, 2001) and Chlamydia psittaci is an important zoonotic 41 
agent associated with atypical pneumonia as well as systemic infections (Knittler and 42 
Sachse, 2015; Schachter, 1986). In the past decades, various Chlamydia-related bacteria 43 
have been discovered, notably Simkania negevensis (S. negevensis). These bacteria have 44 
been classified in the Chlamydiales order, as they exhibit a biphasic developmental cycle 45 
with infectious Elementary Bodies (EBs) and replicative Reticulate Bodies (RBs) similar 46 
to what is known for Chlamydia spp.. Growing evidence suggests a pathogenic role for 47 
many of these Chlamydia-related bacteria mainly in respiratory diseases and in obstetrical 48 
complications (Baud et al., 2014, 2008; Corsaro and Greub, 2006; Greub, 2009; Greub et 49 
al., 2003a; Greub and Raoult, 2002a; Lamoth and Greub, 2010). Due to the lack of 50 
commercial diagnosis methods and clinical guidelines, these strict intracellular bacteria 51 
are, however, not routinely screened in the clinic. It is therefore essential to better 52 
understand the biology and to clearly define their clinical importance as they may 53 
represent important human pathogens.  54 
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In this review, we summarize the current knowledge on S. negevensis and explore future 55 
research challenges.56 
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HISTORY 57 
S. negevensis was discovered in 1993 as a cell culture contaminant. In their first report, 58 
Simona Kahane et al. describe the micro-organism “Z” as an intracellular bacterium, 59 
which exhibited a two-phase replicative cycle similar to Chlamydia spp.. However, it was 60 
not recognized by Chlamydia-specific PCR primers, nor by Chlamydia-specific 61 
antibodies (Kahane et al., 1993). The analysis of the 16S rRNA encoding gene showed an 62 
83% homology with Chlamydia spp. and 73% with Rickettsia (Kahane et al., 1995); the 63 
authors concluded to the discovery of a new Chlamydia-like bacterium. To better 64 
characterize the relationship of the microorganism with members of the Chlamydiaceae 65 
family, the 16S/23S rRNA intergenic spacer and Domain I of the rRNA encoding gene of 66 
these species were analyzed (Everett and Andersen, 1997). This work led to the 67 
description of the Simkaniaceae family within the Chlamydiales order with the 68 
microorganism Simkania «Z» as a founding member. It was renamed, afterwards, 69 
Simkania negevensis in honor of Simona Kahane from the Ben-Gurion University of 70 
Negev, Israel (Everett et al., 1999a).  71 
S. negevensis was the first Chlamydia-like organism described. Its discovery gave an 72 
insight of the wide ecological diversity of the Chlamydiales order, and opened new 73 
research fields. Indeed, in the past decade, various Chlamydia-like organisms have been 74 
discovered (Corsaro and Greub, 2006; Corsaro and Venditti, 2009; Horn, 2008; Lienard 75 
et al., 2011b), notably using amoebal co-culture techniques (Jacquier et al., 2013). In 76 
1999, based on the percentage of the 16S and 23S rRNA encoding genes sequences 77 
similarities (>80 and <90%), Everett et al., proposed, in addition to the Simkaniaceae 78 
family, two novel families within the Chlamydiales order: the Waddliaceae and the 79 
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Parachlamydiaceae (Everett et al., 1999a). These “Everett” cut-offs have been validated 80 
by the International Subcommittee of Taxonomy (Greub, 2010) and have been recently 81 
extended by Pillonel et al. to use 6 additional taxonomically informative genes (Pillonel 82 
et al., 2015). Currently, the order is divided in nine family-level lineages, namely the 83 
Chlamydiaceae, Clavichlamydiaceae, Criblamydiaceae, Parachlamydiaceae, 84 
Parilichlamydiaceae, Piscichlamydiaceae, , Rhabdochlamydiaceae, Simkaniaceae and 85 
Waddliaceae (Bavoil et al., 2013; Stride et al., 2013). Such division might however only 86 
represent a small portion of the ecological diversity of this order as suggested by 87 
Lagkouvardos et al., who estimate that more than 180 potential family-level lineages 88 
likely exist (Lagkouvardos et al., 2014). 89 
 90 
MICROBIOLOGY 91 
Simkaniaceae diversity  92 
The Simkania genus belongs to the Simkaniaceae family, within the Chlamydiales order 93 
and consists of a single species, S. negevensis. Simkaniaceae comprise 3 genera: 94 
Simkania, Fritschea and Syngnamydia; the latter two genera are reported as Candidatus 95 
strains, since they have not been yet recovered by culture. Fritschea were first identified 96 
in 2003 as endosymbionts of arthropods and are subdivided in 2 Candidatus species: F. 97 
bemisiae and F. eriococci (Everett et al., 2005; Thao et al., 2003; Xue et al., 2012). 98 
Syngnamydia, which also includes 2 Candidatus species (S. venezia and S. salmonis), 99 
were recently described as pathogens in fishes, causing epitheliocystis, a disease 100 
characterized by large cysts in the gills (Fehr et al., 2013; Nylund et al., 2014). 101 
Additionally, seven DNA sequences recovered in environmental samples were recently 102 
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described as putative members of the Simkaniaceae family based on their 16S rRNA and 103 
23S rRNA encoding genes sequences. The first sequence (EF177461) was recovered in 104 
gastrodermal cells of Xenoturbella, a primitive marine worm (Israelsson, 2007). Three 105 
other sequences (FJ976094, FJ976095 and AF448723.3) were identified in environmental 106 
water samples and grouped as the cvE9 cluster (cvE38, cvE41 and cvE9) (Corsaro et al., 107 
2002; Corsaro and Venditti, 2009). The last three were recovered from unicellular 108 
eukaryotes present in the ocean crust and from citrus plants suffering from the Yellow 109 
dragon disease (Huanglongbing), a mortal disease in citrus, caused by vector transmitted 110 
Gram-negative bacteria (Sagaram et al., 2009; Santelli et al., 2008)  111 
 112 
Simkania negevensis: genome and evolution 113 
All Chlamydiales derived from a Chlamydiae/Planctomycetes/Verrucomicrobia common 114 
ancestor (Budd and Devos, 2012). Three evolutionary clusters appear to exist: (i) the 115 
Chlamydiaceae/Clavichlamydiaceae cluster, which harbors the smallest genomes and 116 
seems to have branched the earliest, (ii) the 117 
Parachlamydiaceae/Waddliaceae/Criblamydiaceae cluster and (iii) the 118 
Simkaniaceae/Rhabdochlamydiaceae cluster (Lagkouvardos et al., 2014). Indeed, 119 
Simkaniaceae share an 86-87% homology in the 16S rRNA encoding gene sequence with 120 
Rhabdochlamydiaceae (Kostanjsek et al., 2004) and only 82% homology with 121 
Chlamydiaceae (Kahane et al., 1995). Comparative analysis of the full genome sequences 122 
showed more than 400 conserved core genes preserved in all Chlamydiales members 123 
(Bertelli et al., 2010; Collingro et al., 2011; Pillonel et al., 2015). Among them, 20 are 124 
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highly informative taxonomically and should be preferentially used to assign new strains 125 
at species level (Pillonel et al., 2015).  126 
S. negevensis genome is characterized by a 2-3 fold larger size compared to the 127 
Chlamydiaceae members, but comparable to the genome size of Waddliaceae and 128 
Parachlamydiaceae members (Collingro et al., 2011), as shown in table 1. This suggests 129 
a large biosynthetic ability, allowing adaptation to various environments. The analysis of 130 
S. negevensis genome revealed the presence of a type I intron localized in the 23S rRNA 131 
gene (Everett et al., 1999b). Type I introns are self-splicing motile introns, which have so 132 
far only been described in eukaryotic cells. To date, S. negevensis and Coxiella burnetii 133 
are the only bacterial species, which possess such genetic structure (Nesbø and Doolittle, 134 
2003). This molecular pattern is also present in the amoeba Acanthamoeba castellanii as 135 
well as in the algal chloroplasts (Everett et al., 1999b) and therefore may have been 136 
acquired from horizontal gene transfer. This discovery, along with the high proportion of 137 
eukaryotic-like genes in chlamydial genomes, questions the possible relationship between 138 
Chlamydiales and chloroplasts and their possible implication in the eukaryiogenesis 139 
(Brinkman et al., 2002). The function of this intron remains unclear, but evidence showed 140 
that the intron is not spliced from the 23S rRNA and might delay growth by reducing 141 
ribosomal function (Everett et al., 1999b). It is not known whether this intron was also 142 
present, at first, in other Chlamydiales growing in amoebae and was subsequently 143 
eliminated to improve replication or whether it was horizontally acquired after the 144 
divergence of S. negevensis from other Chlamydiales. 145 
S. negevensis possess a 132kb plasmid, which carries a type IV secretion system (T4SS) 146 
encoded by a tra operon. A similar tra operon is also present in the genome of 147 
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Protochlamydia amoebophila (Greub et al., 2004a) and of Parachlamydia 148 
acanthamoebae (Greub et al., 2009), two members of the Parachlamydiaceae family. 149 
These operons exhibit a striking similarity with the tra genes carried by the conjugative 150 
F-plasmid of Escherichia coli. Thus, it is suspected that these chlamydial operons encode 151 
a conjugative DNA transfer system. In addition, the S. negevensis tra operon also exhibits 152 
genetic similarities to the T4SS conjugative system encoded in Rickettsia belli, where 153 
conjugation has been demonstrated (Ogata et al., 2006), reinforcing the putative role of 154 
the S. negevensis T4SS in DNA transfer. Independent of the presence of the T4SS, the 155 
identification of a plasmid in the S. negevensis genome is of utmost interest, as it might 156 
play a significant role in the pathogenesis of S. negevensis infection, as suggested for the 157 
7’500kb Chlamydia spp. plasmid. Indeed, it has been shown both in vivo (Kari et al., 158 
2011; O’Connell et al., 2007) and in vitro (Porcella et al., 2015) that infections with a 159 
plasmid deficient strain resulted in attenuated infections exhibiting a lower inflammatory 160 
response. An adaptive immune response was however elicited enabling protection against 161 
re-infection (Kari et al., 2011; O’Connell et al., 2007; Porcella et al., 2015). The 162 
mechanisms by which the chlamydial plasmid modulates the pathogenesis are still 163 
unclear, but they are probably related to: (i) direct effect of proteins encoded by the 164 
plasmid (Liu et al., 2014, p. 201; Li et al., 2008) and (ii) regulation of the expression of 165 
other virulence factors encoded by the chromosome (Carlson et al., 2008; Song et al., 166 
2013). Interestingly, the S. negevensis plasmid encodes various proteins of interest, 167 
among which one copy of the Macrophage Infectivity Potentiator (Mip) (Collingro et al., 168 
2011). This lipoprotein is highly similar to the Mip protein of Legionella pneumophila. In 169 
Chlamydia, it has been shown to be essential for an optimal intracellular infection and to 170 
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induce the production of pro-inflammatory cytokines (Bas et al., 2008; Lundemose et al., 171 
1993a, 1993b).  172 
 173 
Biochemical characteristics  174 
Cell wall and surface proteins. The composition of the outer membrane is of significant 175 
importance for the pathogenesis of Chlamydiales. In the EB state, membrane proteins are 176 
implicated in the entry within the host and serve as major antigens for the immune 177 
response. In the RB state, membrane proteins may be part of the secretion systems used 178 
to corrupt the host cell whereas others may serve as porins to uptake nutrients from the 179 
host cytoplasm. A comparison of the structure of the membrane of various members of 180 
the Chlamydiales order is shown in table 1.  181 
The Chlamydial Outer Membrane Complex (COMC) of the Chlamydiaceae is mainly 182 
composed by the MOMP (ompA) protein and by 2 cystein-rich proteins, OmcA and 183 
OmcB (Caldwell et al., 1981). MOMP (ompA) represents 60% of the surface proteins, at 184 
least in purified EBs and serves as a porin (Bavoil et al., 1984). Aistleitner et al. have 185 
recently studied the structure of S. negevensis outer membrane (Aistleitner et al., 2014). 186 
Using a computerized proteomic approach, 65 OMPs were identified as major 187 
components of the S. negevensis EB’s membrane. Among them 37 were MOMP-like 188 
proteins, which resemble the MOMP (ompA) of Chlamydiaceae. Out of the 37 MOMP-189 
like proteins, 30 contained beta-sheet conformations, suggesting a role as porins. Two of 190 
them demonstrated high similarity to MOMP proteins of veterinary Chlamydia species 191 
(Collingro et al., 2011). S. negevensis outer membrane lacks the cysteine-rich proteins 192 
(OmcA and OmcB) present in other Chlamydiales. These cysteine-rich proteins are 193 
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sensitive to the redox state of the environment and they might provide some rigidity and 194 
resistance to osmotic pressure through the formation of disulfide bridges. Some authors 195 
suggested that they may replace the peptidoglycan layer present in the periplasm of other 196 
Gram-negative bacteria (Everett and Hatch, 1995; Sun et al., 2007). No homologues of 197 
OmcA and OmcB were identified in S. negevensis genome and none of the identified 198 
MOMP-like proteins could serve this function as their content in cysteine was extremely 199 
low (Aistleitner et al., 2014). Such differences may result in a more flexible envelope and 200 
a lack of surface proteins regulated by the redox state. Such regulations are associated 201 
with modifications of the function of several surface proteins in Chlamydiaceae through 202 
reduction and reoxidation of the cysteine residues and could play a role in the switch 203 
from the EB to the RB state. For example, the permeability of MOMP is increased once 204 
reduced (Bavoil et al., 1984) and the type III secretion system (T3SS) in Chlamydia is 205 
also described as influenced by the redox state (Betts-Hampikian and Fields, 2011). 206 
Studying the morphology of EBs and RBs particles is difficult and has been the subject of 207 
various works. As an example, crescent bodies and star bodies were reported as infectious 208 
EB-like particles of Parachlamydiaceae and Criblamydiaceae, respectively (Lienard et 209 
al., 2011b; Rusconi et al., 2013; Thomas et al., 2006). Current knowledge suggests that 210 
these observations are largely influenced by the buffer and the fixatives used and 211 
therefore do not allow taxonomic discrimination, even if they correspond to some 212 
structural differences in the cell wall of the different bacterial families (Pilhofer et al., 213 
2014; Rusconi et al., 2013). Noteworthy, S. negevensis EBs were described as highly 214 
pleomorphic particles, especially once located in the cytoplasm (Pilhofer et al., 2014). 215 
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Such observation reinforces the hypothesis of a relative high cell wall flexibility due to 216 
the lack of cysteine-rich surface proteins in S. negevensis. 217 
 218 
The inner membrane of most bacteria is protected by a cell wall composed of 219 
peptidoglycan. This structure is important for membrane stability as well as cell division. 220 
Until recently, it was thought that Chlamydiales were lacking peptidoglycan and their 221 
partial sensitivity to cell wall inhibitors such as penicillin was therefore not understood 222 
and considered as a paradox called the Chlamydiales anomaly. However, the presence of 223 
peptidoglycan was recently demonstrated in some members of the Chlamydiales, namely 224 
C. trachomatis, in which they were present as a ring structure at the division septum 225 
(Liechti et al., 2014) and P. amoebophila, which synthesizes sacculi that contain a 226 
modified form of peptidoglycan (Pilhofer et al., 2013). Additionally, a recent work 227 
identified two peptidoglycan-remodeling enzymes (the AmiA amidase and the NlpD 228 
endopeptidase) implicated in coordinated cell wall constriction during division. Such 229 
enzymes were shown to recognize peptidoglycan-like peptides in Chlamydiales (Frandi et 230 
al., 2014). Most of this work was done on Waddlia chondrophila, a Chlamydiales 231 
member that is susceptible to high dose of penicillin and also to fosfomycin, a drug active 232 
on MurA (Frandi et al., 2014; Jacquier et al., 2014). The MurA enzyme is implicated in 233 
peptidoglycan biosynthesis, suggesting the presence of peptidoglycan-like structures in at 234 
least 3 family-level lineages of the Chlamydiales order, namely the Chlamydiaceae, 235 
Waddliaceae and Parachlamydiaceae (Frandi et al., 2014; Jacquier et al., 2015, 2014). In 236 
their first report, Kahane et al. described S. negevensis as being resistant to 10µg/ml of 237 
penicillin, as opposed to what was observed for C. trachomatis. It was, however, 238 
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sensitive to cycloserine, an inhibitor of the peptidoglycan synthesis, similarly to other 239 
Chlamydiaceae. In addition, activity of the AmiA amidase and the NlpD endopeptidase 240 
was, recently, documented in S. negevensis, suggesting the presence of peptidoglycan-241 
like structures in S. negevensis (Frandi et al., 2014), despite failure to isolate 242 
peptidoglycan containing sacculi in S. negevensis (Liechti et al., 2014). Their detection 243 
might be prevented by a restricted time-frame synthesis (Jacquier et al., 2015) or might 244 
require an additional method, similar to the one recently described by Packlam et al., 245 
which allowed the isolation of peptidoglycan fragments in C. trachomatis (Packiam et al., 246 
2015). 247 
 248 
Secretion systems. Intracellular bacteria parasitize their host’s metabolic pathways to 249 
their own advantage. In parallel, they must inhibit the trigger of the host’s immune 250 
system. One strategy consists in secreting various proteins into the host cytoplasm or 251 
environment through secretion systems (Greub, 2013). S. negevensis encodes a Type III 252 
secretion system (T3SS) (Collingro et al., 2011). Hsia el al. first suggested the existence 253 
of a type III secretion system in Chlamydia (Hsia et al., 1997), which was likely present 254 
in the Chlamydiales common ancestor given its presence in every genome sequenced so 255 
far (Bertelli et al., 2015, 2010; Greub et al., 2009; Horn et al., 2004; Hovis et al., 2013; 256 
Stephens et al., 1998), as summarized in table 1. The T3SS appears as a needle inserted in 257 
the inner and outer membranes of the bacterium, which protrudes into the cytoplasm of 258 
the cell through the inclusion membrane (Pilhofer et al., 2013). Although, the structure of 259 
the T3SS is highly conserved among Chlamydiales, effectors secreted through this 260 
system largely vary among families and genera (Collingro et al., 2011). Interestingly, S. 261 
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negevensis does not possess genes encoding for major chaperones of the T3SS, namely 262 
the SctF, CdsF, CT666 and the Specific Chlamydiales Chaperon 3 (SCC3), which are 263 
conserved in Waddliaceae, Parachlamydiaceae and Chlamydiaceae (Collingro et al., 264 
2011).  265 
As mentioned above, S. negevensis plasmid encodes a T4SS. In addition to its likely role 266 
in plasmid propagation and DNA exchange, it may also allow secretion of proteins and 267 
may represent an important virulence factor.  268 
 269 
Metabolism. Strict intracellular bacteria are often characterized by their important lack 270 
of metabolic pathways and the necessity to parasitize their hosts for nutrients and energy. 271 
However, genomic studies have revealed extended metabolic capabilities of S. negevensis 272 
compared to Chlamydiaceae (Collingro et al., 2011; Omsland et al., 2014). This extended 273 
metabolic capacity has also been observed for other Chlamydia-related bacteria 274 
exhibiting large genomes (Bertelli et al., 2010; Collingro et al., 2011; Greub et al., 2009; 275 
Horn et al., 2004), as shown in Table 1. Among major differences, we note their ability to 276 
directly use glucose for the glycolysis pathway due to the presence of a glucokinase, 277 
making them independent from the host cell glucose-6-phosphate (Bertelli et al., 2010; 278 
Collingro et al., 2011; Greub et al., 2009; Omsland et al., 2014). Additionally, they 279 
possess a complete citric acid cycle as opposed to Chlamydiaceae, which lack important 280 
enzymes and need a constant exchange with the host cell to produce energy by oxidation 281 
of acetyl-CoA (Omsland et al., 2014). In S. negevensis, entry in the citrate cycle can 282 
occur: (a) through acetyl-CoA produced from pyruvate following glycolysis and (b) 283 
through the transformation of asparagine in fumarate (Collingro et al., 2011; Omsland et 284 
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al., 2014). Moreover, Waddliaceae, Parachlamydiaceae and Simkaniaceae are able to 285 
synthetize NAD+ from nicotinamide (Bertelli et al., 2010; Omsland et al., 2014) and S. 286 
negevensis can, additionally, use asparagine as a source of NAD+ (Collingro et al., 2011; 287 
Knab et al., 2011; Omsland et al., 2014). Finally, an in vitro experiment by Kahane et al. 288 
suggests that S. negevensis is able to grow in a glucose free medium; indeed the number 289 
of infectious forming units was similar using a Roswell Park Memorial Institute (RPMI) 290 
media depleted in glucose and supplemented with 1% glucose (Kahane et al., 1999). 291 
Taken together, these findings suggest that S. negevensis is less dependent from the host 292 
cell in term of energy production compared to other Chlamydiales (Omsland et al., 2014).  293 
Similarly to Chlamydiaceae, S. negevensis is unable to synthesize nucleotides de novo 294 
and relies on nucleotides transporters for their uptake. Four isoforms of nucleotides 295 
transporters have been identified in S. negevensis: SnSTT1, an ADP/ATP antiporter; 296 
SnSTT2, a guanine/ATP/H+ symporter; SnSTT3 a global nucleotide triphosphate 297 
antiporter, also able to transport deoxy-CTP (dCTP). The function of the last transporter, 298 
SnSTT4, is unknown (Knab et al., 2011). The ability to transport dCTP is unique among 299 
prokaryotes and might represent a selective metabolic advantage for S. negevensis, 300 
favoring its relative growth in environments rich in cytosine. 301 
Regarding amino-acid biosynthesis, S. negevensis is able to synthesize tyrosine, 302 
phenylalanine, proline, alanine, aspartate and glutamate (Collingro et al., 2011; Omsland 303 
et al., 2014). In addition, S. negevensis possesses a complete tryptophan operon (trp 304 
operon) (Collingro et al., 2011; Omsland et al., 2014). Some pathogenic Chlamydiaceae, 305 
notably the genitourinary strains of C. trachomatis, are partially capable of synthesizing 306 
this metabolite but enzymes required in this pathway are completely absent in other 307 
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Chlamydia-related bacteria (Carlson et al., 2006; Omsland et al., 2014). It appears that 308 
tryptophan plays an important role in the pathogenesis of Chlamydia spp. infections. 309 
Tryptophan is, indeed, an important regulator of the chlamydial development cycle 310 
(Bonner et al., 2014). In case of tryptophan depletion, the expression pattern changes and 311 
forces the bacteria into a persistent form (Baud et al., 2008; Brunham and Rey-Ladino, 312 
2005; Ibana et al., 2011). Tryptophan depletion can be induced in humans by IFN-γ 313 
production (Taylor and Feng, 1991). Thus, S. negevensis might be less sensitive do IFN-γ 314 
than Chlamydiaceae, which could play a role in the pathogenesis. 315 
 316 
Culture characteristics  317 
Cell permissiveness and growth cycle. S. negevensis is able to grow and survive in vitro 318 
in mammalian cells such as Vero cells (Kahane et al., 1993), epithelial cells from the 319 
respiratory and genitourinary tract, endothelial cells (Kahane et al., 2007a) as well as 320 
macrophages (Kahane et al., 2008). Growth is also described in arthropods (both in vitro 321 
and in vivo) (Croxatto et al., 2014; Sixt et al., 2012), and amoebae (Kahane et al., 2001).  322 
Similarly to other Chlamydiales, S. negevensis growth cycle is characterized by the 323 
presence of two developmental stages: one large replicative form (Reticulate Body, RB) 324 
and one small compact form, which resembles to electron dense (Elementary Body, EB) 325 
form of Chlamydiaceae. These two forms can be selectively fractionated on density 326 
gradients (Kahane et al., 1999, 1993). The high density of EBs is likely due to the 327 
presence of condensed DNA as shown by the presence of filamentous material on 328 
electron microscopy tomography (EMT). Even though gene expression might be 329 
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downregulated through DNA condensation, EB particles are likely to be metabolically 330 
active as suggested by the presence of ribosomes (Pilhofer et al., 2014).  331 
 332 
The growth cycle of S. negevensis is characterized by a production phase lasting 333 
approximately 3 days, during which particles are produced in an exponential way. During 334 
that time, the cytoplasm of the host cells shows increasing dark perinuclear patches. This 335 
is followed by a plateau phase, during which no or few particles are produced, but instead 336 
the particles previously produced are stored in multiple large cytoplasmic vacuoles of the 337 
host cells and cytopathic changes are observed. Based on culture observations, S. 338 
negevensis does not seem to induce cell lysis, or at least not to the same extent as what is 339 
observed for other members of the Chlamydiales order, such as W. chondrophila (Kebbi-340 
Beghdadi et al., 2011) In comparison, C. trachomatis particles are released between 30 to 341 
68 hours post infection depending on the strain (Miyairi et al., 2006), W. chondrophila 342 
particles are released 48-72 hours upon cell lysis (Goy et al., 2008) and P. 343 
acanthamoebae induces lysis of infected amoebae after 72-96 hours depending on the 344 
initial Multiplicity Of Infection (MOI) and incubation temperature (Greub et al., 2003b; 345 
Greub and Raoult, 2002b). However, despite the apparent absence of cell lysis, some 346 
particles seem to be released in the extracellular environment, as suggested by the 347 
presence of S. negevensis particles in the supernatant of infected insect cell cultures 348 
capable of inducing a second round of infection (Sixt et al., 2012). Recently, Hybiske et 349 
al. showed that C. trachomatis may exit from the host cell through the extrusion of a 350 
membrane-bound compartment (Hybiske and Stephens, 2007). This extrusion depended 351 
on actin polymerization, as well as on various proteins implicated in the remodeling of 352 
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the cytoskeleton. A similar mechanism might be implicated in the extrusion of S. 353 
negevensis.  354 
Interestingly, it has been proposed that S. negevensis RBs might be infectious, an aspect 355 
that has not been observed for other Chlamydiales so far. Indeed, Kahane et al, observed 356 
similar growth kinetics of S. negevensis purified EBs and RBs (Kahane et al., 2002). 357 
However, this has not been confirmed yet and further investigations are needed before 358 
making any definite conclusions. 359 
 360 
The Simkania containing vacuole and its interaction with cellular organelles. S. 361 
negevensis replicates in a single intracellular vacuole hereafter called the Simkania 362 
Containing Vacuole (SCV). Interestingly, the SCV is closely associated with the 363 
endoplasmic reticulum (ER) of the host cell, being almost completely surrounded by the 364 
typical ribosmes-covered ER membrane (Mehlitz et al., 2014; Pilhofer et al., 2014). Such 365 
ER recruitment was observed in infected epithelial cells, macrophages-derived cells and 366 
amoebae, emphasizing the strong conservation of the phenotype. Intracellular traffic of S. 367 
negevensis clearly differs from P. acanthamoebae, which survives in the late endosome 368 
(Greub et al., 2005) and from C. trachomatis, which intercepts Golgi-derived vesicles and 369 
causes Golgi apparatus fragmentation (Heuer et al., 2009). Recruitment of the ER also 370 
occurs upon infection with other members of the Chlamydiales order, such as C. 371 
trachomatis and W. chondrophila, but to a lesser extent than what is observed following 372 
S. negevensis infection (reviewed in Derré, 2015). The mechanisms by which S. 373 
negevensis induces this tight association remain to be elucidated, but might rely on 374 
specific inclusion proteins or type III effector proteins. Indeed, Chlamydia spp. use their 375 
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IncD protein to recruit the host ER-CERT protein to acquire ceramide (Derré et al., 376 
2011). A recent work suggested that early retrograde transport is required to achieve an 377 
optimal S. negevensis infection, which seems to be implicated both in the SCV 378 
maturation, as well as in lipids uptake (Herweg et al., 2015). This was shown by the 379 
enrichment, at the SCV membrane, of Clathrin and COP1 related proteins, typical of the 380 
early endosomes and Trans-Golgi Network (TGN). This hypothesis is further supported 381 
by the reduced bacterial replication observed in the presence of specific retrograde 382 
transport inhibitors. In addition, ceramide vacuolar uptake was modified by these 383 
inhibitors, suggesting that S. negevensis has developed a mechanism to directly obtain 384 
ceramides from the Golgi.  385 
The tight association observed between the SCV and the ER raises the question of 386 
activation of the ER-stress, which plays a significant role in limiting viral replication. 387 
Interestingly, S. negevensis is capable of inhibiting the ER-stress response despite a 388 
strong initial activation, and thus promoting host survival and indirectly promoting S. 389 
negevensis replication (Mehlitz et al., 2014). 390 
In addition to the strong ER association, some recruitment of mitochondria at the SCV 391 
was observed in mammal’s cells, similarly to what is observed for W. chondrophila 392 
(Croxatto and Greub, 2010) and C. psittaci (Mehlitz et al., 2014). However, the 393 
phenotype of mitochondria association to the replicative vacuole is much stronger for W. 394 
chondrophila, which recruits mitochondria as early as 3 hours post-infection using a 395 
redundant mechanism based on both microtubules and actin microfilaments (Croxatto 396 
and Greub, 2010). Mitochondria might represent an additional source of lipids, as well as 397 
ATP (Croxatto and Greub, 2010). It is still unclear whether S. negevensis has developed a 398 
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specific mechanism to recruit the mitochondria, or if their association to the SCV is 399 
related to their natural association with the ER  400 
401 
   
21 
 
EPIDEMIOLOGY 402 
Prevalence  403 
Scarce data on the prevalence of Simkania are available in the literature, most of them 404 
provided by old studies. Caution should be taken when interpreting these results. The 405 
seroprevalence appears high in the Middle East (Israel and Jordanian), ranging from 55-406 
65% among healthy adults and reaching 80% in Bedouins (Al-Younes and Paldanius, 407 
2014; Friedman et al., 1999). Serological evidence of past infection was documented in 408 
46% of pregnant women in Cornwall, UK (Friedman et al., 2006) and in 41% of Danish 409 
blood donors (Johnsen et al., 2005). In contrast, an overall prevalence of only 23.5% was 410 
observed among children and adults in Brooklyn, USA (Kumar et al., 2005) and only 411 
4.5% of the population tested in Japan were seropositive, a low prevalence observed 412 
despite the low cut-off titer of 1:8 used in the study (Yamaguchi et al., 2005). The large 413 
discrepancy between these results could be explained by geographical differences in term 414 
of exposure and risk factors. However, the heterogeneity of diagnostic tools used between 415 
the studies makes comparisons difficult. Indeed, the prevalence observed in the Danish 416 
and Jordanian population was obtained using an immunofluorescence assay with a cut-off 417 
titer of 1:16 and 1:8, respectively, which probably overestimated the prevalence (Al-418 
Younes and Paldanius, 2014; Johnsen et al., 2005). Nevertheless, the relatively high 419 
prevalence in Israel, England and USA was observed using the same ELISA assay based 420 
on purified EBs (Friedman et al., 2006, 1999; Kumar et al., 2005). Authors tested a 1/100 421 
diluted serum and considered an OD (optical density) higher than 0.5 as positive. In 422 
conclusion, serological evidence of human exposure to Simkania infection was 423 
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documented worldwide and prevalence seems to increase with increasing age (Friedman 424 
et al., 2006; Johnsen et al., 2005; Kumar et al., 2005). 425 
 426 
Transmission and reservoir  427 
S. negevensis was discovered as a cell culture contaminant. However, the natural host of 428 
Simkaniaceae remains unknown. As mentioned above, S. negevensis is able to grow in 429 
vitro in a wide range of hosts (i.e. mammalian cells, arthropods, amoebae) (Kahane et al., 430 
2008, 2007a, 2001; Sixt et al., 2012). Evidence of Simkaniaceae was documented in vivo 431 
in ticks (Croxatto et al., 2014; Pilloux et al., 2015) and in granulomatous lesions in 432 
reptiles (Soldati et al., 2004). Fritschea were discovered in arthropods (Everett et al., 433 
2005) and Syngdamydia in fish (Fehr et al., 2013; Nylund et al., 2014). Additionally, 434 
various Simkania-related DNA sequences were amplified from marine environments 435 
(Israelsson, 2007; Santelli et al., 2008) and in one case in vegetal cells (Sagaram et al., 436 
2009). This wide host range is quite impressive and contrasts with the narrow host range 437 
of Chlamydia trachomatis (human-specific) and Chlamydia felis (cat-specific).  438 
 439 
Various hypotheses on the reservoir of Simkaniaceae and their mode of transmission to 440 
humans have been proposed. Firstly, contaminated water might be a source of human 441 
infection, either as a free-living organism or through infected amoebae. Indeed, a report 442 
showed that S. negevensis infectivity in vitro was still preserved after a 7 days incubation 443 
of free particles in distilled water and was even increased in cases of co-infection with 444 
amoebae (Kahane et al., 2004). In comparison, the infectivity of C. trachomatis, 445 
considered as a sexually transmitted disease, was completely abolished after 5 hours of 446 
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incubation in the same conditions (Kahane et al., 2004). Moreover, co-culture of 447 
macrophages with S. negevensis-infected amoebae resulted in the rapid death of the 448 
amoebae and infection of the macrophages (Kahane et al., 2008). Amoebae could 449 
therefore serve as reservoir and contribute to the selection of virulence traits (Greub and 450 
Raoult, 2004; Lamoth and Greub, 2010). This is in agreement with the identification of 451 
Simkania and amoebae’s antigens in drinking water and in reclaimed wastewater used to 452 
irrigate crop in Israel (Donati et al., 2015; Kahane et al., 2004). Similarly, Simkania DNA 453 
was amplified from environmental water in Western Europe (Corsaro et al., 2002; 454 
Corsaro and Venditti, 2009) and, recently, in Italian swimming pools (Donati et al., 2015; 455 
Pérez et al., 2012, 2011). Transmission to humans through water is also suggested by a 456 
prospective study, in which it was possible to identify the presence of Simkania in the 457 
corresponding drinking water of children suffering from a Simkania-associated 458 
pneumonia in as much as 76.5% of cases. In this study, results were only considered as 459 
positive when congruent results were obtained by at least two different approaches 460 
(Nested PCR, culture in Vero cells and/or Membrane Enzyme Immuno-Assay (MEIA)) 461 
(Kahane et al., 2007b). Nevertheless, these results should be treated with caution as (i) 462 
only 34 children were included in the study and (ii) nested PCR contamination cannot be 463 
excluded due to the very high proportions of positive results observed in the study. 464 
Finally, an oral transmission of S. negevensis is likely since (i) a significant IgA response 465 
to Simkania was observed in patients with gastro-intestinal symptoms (Donati et al., 466 
2013) and (ii) S. negevensis may replicate in vitro within gastro-intestinal cell lines 467 
(Kahane et al., 2007a).  468 
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Arthropods, such as ticks, might represent another source of infection. Vector 469 
transmission is quite common for other intracellular bacteria such as Rickettsia (Walker 470 
and Ismail, 2008). Moreover, Simkania-associated DNA was amplified from Swiss 471 
Ixodes ricinus ticks, though with a lower prevalence and amount than 472 
Rhabdochlamydiaceae (Croxatto et al., 2014; Pilloux et al., 2015).  473 
Additional hypotheses of transmission include direct human to human transmission 474 
through aerosols or droplets due to the association with respiratory diseases (see 475 
pathogenic potential, hereafter), as well as sexual contacts or contacts with animals, 476 
which were described for other Chlamydiales (Baud et al., 2007; Baud and Greub, 2011; 477 
Gottlieb et al., 2013; Knittler and Sachse, 2015; Schachter, 1986). Sexual contact seems 478 
unlikely due to the high prevalence in children and the absence of cross-prevalence with 479 
C. trachomatis (Friedman et al., 1999). Finally, a zoonotic transmission has so far not 480 
been documented, but cannot be excluded.  481 
482 
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PATHOGENIC POTENTIAL  483 
In vitro 484 
Several in vitro aspects of S. negevensis infection suggest an important pathogenic 485 
potential. First, S. negevensis is able to grow and survive within macrophage-type cell 486 
line U937 (Kahane et al., 2008). Moreover, uninfected epithelial cells can be actively 487 
infected after co-culture with infected macrophages (Kahane et al., 2008). Interestingly, 488 
S. negevensis is resistant in vitro to LL-37 cathelicidin human peptide present in 489 
phagocyte cells, but is highly sensitive to 5 other animal cathelicidins (Donati et al., 490 
2011). Moreover, Karunakaran et al. demonstrated that S. negevensis prevents TNF-α-491 
induced apoptosis in host cells through the inhibition of the release of mitochondrial 492 
caspase-activating proteins (Karunakaran et al., 2011). This is similar to what is known 493 
for the pathogenic C. trachomatis and C. pneumoniae (Fan et al., 1998). However, the 494 
phenotype seems to be stronger in S. negevensis as it could be observed even at a very 495 
low MOI (MOI=0.5) (Fan et al., 1998; Karunakaran et al., 2011). This anti-apoptotic 496 
capability represents an important virulence factor and is not observed in all 497 
Chlamydiales. For example, Parachlamydiaceae appear to instead induce apoptosis in 498 
macrophages (Greub et al., 2003c) and in insect cell lines (Sixt et al., 2012). The ability 499 
to inhibit apoptosis and the absence of cell lysis might allow S. negevensis to persist 500 
within its host and establish a persistent latent infection. Such infection might then be 501 
reactivated and might represent an important pathogenic mechanism.  502 
Two types of S. negevensis infection have been described: (i) an active infection with 503 
production of new bacterial particles and observation of cytopathic effects in the host, 504 
and (ii) a persistent infection without any cytopathic effects (Kahane et al., 2007a). In 505 
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persistent infection, mostly RBs of atypical morphology were visualized within the 506 
infected cells. Persistence of infectious particles within the host was demonstrated by 507 
inoculation of uninfected Vero cells with persistently infected cells, which produced an 508 
active infection. Infection was however less efficient compared to inoculation with 509 
actively infected cells. 510 
In Chlamydia spp., persistence may be induced by iron depletion (Raulston, 1997), IFN-γ 511 
(Beatty et al., 1994; Rottenberg et al., 2002) and penicillin treatment (Matsumoto and 512 
Manire, 1970). With S. negevensis, a latent infection can be observed either 513 
spontaneously in specific cell lines, namely intestinal or genitourinary lines, or could be 514 
induced by iron depletion. Reactivation was then possible after serial trypsin treatment 515 
(Kahane et al., 2007a). Interestingly, reactivation was also observed when persistently 516 
infected cells were cultured with macrophages-derived cells. The mechanism, by which 517 
reactivation is induced, is still unclear, but might rely on recognition of the infection by 518 
the macrophages and production of cytokines, which could promote the release of 519 
infectious S. negevensis particles (Kahane et al., 2008). In addition, an inflammatory 520 
response was observed in both types of infections, mostly through the production of IL-8 521 
and IL-6 (Kahane et al., 2007a). 522 
 523 
Lessons from the clinic 524 
Since the discovery of S. negevensis, only few studies have been conducted to evaluate 525 
the implication of Simkania spp. in human diseases (see list of all studies in 526 
supplementary materials). An implication in respiratory diseases, particularly in 527 
bronchiolitis and pneumonia in children and young adults, is likely, as shown in tables 2 528 
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and 3, respectively, which summarize the findings of major clinical studies. Thus, a 529 
significant association between Simkania and acute bronchiolitis was shown in children 530 
from Israel (Kahane et al., 1998). The authors used both a PCR and a cell culture 531 
approach to detect the organism in nasopharyngeal samples. A total of 239 patients and 532 
78 controls were included over a period of two years. Of the 116 patients, from whom a 533 
possible etiologic agent was isolated, 60 were positive for Simkania by at least one of the 534 
techniques used. This was the second most common agent identified after respiratory 535 
syncitial virus (RSV) and statistically different from controls. Clinical findings were 536 
similar to patients infected by RSV. Similar results were also obtained in a study 537 
performed on English children with bronchiolitis. In 26% of the patients, evidence of a 538 
Simkania infection was provided by both PCR and culture. This rate reached 45% when 539 
considering only samples positive by PCR. However no controls were included in this 540 
study (Friedman et al., 2006).  541 
Various works showed evidence of an acute infection with Simkania in cases of 542 
pneumonia in children and young adults (Donati et al., 2011; Fasoli et al., 2008; 543 
Heiskanen-Kosma et al., 2008; Kahane et al., 2007b; Lieberman et al., 1997; Lienard et 544 
al., 2011a; Nascimento-Carvalho et al., 2009). Acute infection was indicated either by a 545 
rise in paired sera of IgG, IgA or IgM defined as a 4 fold increase of antibody titers 546 
observed by micro-immunofluorescence (Fasoli et al., 2008; Heiskanen-Kosma et al., 547 
2008; Nascimento-Carvalho et al., 2009) or a rise of 0.5 OD in the ELISA signal 548 
(Lieberman et al., 1997), or by elevated titers of IgM or IgA or direct identification of 549 
Simkania through PCR, culture or antigen detection (Kahane et al., 2007b). Globally, a 550 
low prevalence of acute infection was observed (2-10%), except in the study performed 551 
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by Kahane et al., in which Simkania was identified in almost all samples, including 552 
controls. Evidence of co-infections with other putative pathogens was found in 40 to 60% 553 
of the cases; the most commonly associated pathogens were Mycoplasma pneumoniae, 554 
RSV, Streptococcus pneumoniae and Chlamydia pneumoniae (Fasoli et al., 2008; 555 
Lieberman et al., 1997; Nascimento-Carvalho et al., 2009). Noteworthy, the association 556 
of Simkania infection with the occurrence of bronchiolitis or pneumonia was not 557 
confirmed in a study performed on children, in Brooklyn, USA (Kumar et al., 2005). 558 
An association between Simkania infection and other respiratory diseases was also 559 
studied. However, no association was found with asthma (Korppi et al., 2006; Kumar et 560 
al., 2005), nor with exacerbation of Chronic Obstructive Pulmonary Disease (COPD) 561 
(Lieberman et al., 2002), chronic cough (Johnsen et al., 2005) or acute lung rejection 562 
(Husain et al., 2007). Results are difficult to interpret owing to low statistical power of 563 
these studies. However, a significant correlation with serological evidence of an acute 564 
infection was shown in unspecified respiratory tract infection among adults, in England 565 
(Friedman et al., 2006) and a higher prevalence of Simkania was documented in patients 566 
with a lung transplant as compared to other immunocompromised patients or 567 
immunocompetent patients (Husain et al., 2007). 568 
 569 
Caution should be taken when interpreting the results since only few studies included a 570 
control group. In addition, the same group from the Ben-Gurion University of the Negev, 571 
in Israel, discovered S. negevensis and performed most of the studies suggesting a 572 
pathogenic role. The specificity of the diagnostic tools might have not been optimal and 573 
contamination could have occurred within the laboratory. Indeed, the prevalence 574 
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observed in the studies performed by this group (26% in Israel (Kahane et al., 1998), 575 
63.6% in Inuit patients (Greenberg et al., 2003) and 80 to 97.5% in lung transplants 576 
(Husain et al., 2007)) are strikingly high, even in the control groups (Kahane et al., 577 
2007b; Kumar et al., 2005).  578 
Moreover, recent studies performed by other groups have failed to confirm such high 579 
prevalence. Indeed, using a specific quantitative PCR, Niemi et al. could not identify any 580 
positive case of Simkania infection in 97 respiratory samples taken from adult patients 581 
with a suspected respiratory tract infection (Niemi et al., 2011). Similarly, only two 582 
samples from Swiss children with bronchiolitis were identified as positive for a 583 
Simkaniaceae infection by a validated pan-Chlamydiales quantitative PCR (Lienard et al., 584 
2011a) and only one case of a co-infection with Simkania and C. psittaci was identified in 585 
a large German study investigating community acquired pneumonia (Dumke et al., 2015). 586 
This discrepancy between the results could either be due to differences in the reliability 587 
of the diagnostic techniques used or to geographical variations of the prevalence of the 588 
infection. 589 
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DIAGNOSIS  590 
Various techniques have been described to diagnose a S. negevensis infection, reviewed 591 
by Corsaro et al. (Corsaro and Greub, 2006). Most of them were developed in the early 592 
2000’s. They may now lack specificity due to the recent discovery of novel Chlamydiales 593 
species.  594 
 595 
Direct identification of Simkania in clinical samples  596 
PCR. PCR is currently the technique of choice to diagnose C. trachomatis or C. 597 
pneumoniae infections. Diagnostic real-time PCRs have also been developed and are 598 
routinely used in our laboratory to detect W. chondrophila, P. acanthamoebae and P. 599 
neagleriophila in clinical samples (Casson et al., 2008a, 2008b; Goy et al., 2009). By 600 
analogy, this technique should be preferentially used to detect Simkania spp.. Most of the 601 
primers and probes developed earlier, which are listed in Table 4, are based on the 602 
detection of amplicons on agarose gel, a technique with a lower sensitivity and specificity 603 
than real-time PCR, at risk of contamination by amplicons. Thus, we currently 604 
recommend the use of a pan-Chlamydiales PCR (Lienard et al., 2011a) followed by 605 
sequencing to detect putative cases of infection.  606 
 607 
Culture. Isolation of organisms through culture is crucial to prove the presence of viable 608 
bacteria in clinical samples and to provide a reference strain for a precise downstream 609 
characterization, as well as to provide antigens for serological assays. Simkania spp. may 610 
be difficult to recover from clinical samples through culture, as it requires cell culture, 611 
which is at risk of contamination by other bacteria present in the flora of non-sterile 612 
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samples such as sputa, nasopharyngeal swabs or vaginal swabs. Owing to these culture 613 
difficulties, the sensitivity of culture seems to be lower than PCR (Corsaro and Greub, 614 
2006; Kahane et al., 1998).  615 
Culture in Vero cells is currently the method of choice to isolate Simkania spp. in clinical 616 
samples (Corsaro and Greub, 2006), although amoebal co-culture might represent an 617 
ideal alternative for respiratory samples, given the non-susceptibility of amoebae to 618 
Mycoplasma and to most bacteria present in the physiological oropharynx flora (Greub et 619 
al., 2004b; Jacquier et al., 2013). Testing the cells used for cell culture for the presence of 620 
a possible contamination should be routinely done; this screening should be able to detect 621 
Mycoplasma spp. as well as Chlamydiales, including S. negevensis, since the later was 622 
first isolated as a cell culture contaminant. We recommend microscopy examination of 623 
cell lines and a Pan-Chlamydiales PCR (Lienard et al., 2011a), when contamination is 624 
suspected.  625 
 626 
Others. Immunohistochemistry based on rabbit or mouse anti-S. negevensis antibodies 627 
may be used to visualize this bacterium in lesions when biopsies are available. By 628 
analogy with other Chlamydiales, Gram staining should be avoided since the results are 629 
inconsistent, as EBs result generally Gram-positive, whereas RBs result Gram-negative 630 
(Lamoth and Greub, 2010). 631 
 632 
Serological studies 633 
Micro-immunofluorescence (MIF) is currently the technique of choice to detect anti-C. 634 
pneumoniae specific antibodies (Dowell et al., 2001). By analogy, this technique should 635 
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also be applied to detect anti-Simkania spp. specific antibodies. Current recommendations 636 
for Chlamydia and Chlamydia-related bacteria propose a cut-off titer of ≥1:64 for IgG to 637 
confirm a past infection and a cut-off of ≥1:32 for IgM for an acute infection (Corsaro 638 
and Greub, 2006). Acute infections may also be documented based on seroconversion 639 
defined as an increase in IgG titer from 0 to ≥1:64 in paired sera or a ≥4-fold rise in the 640 
IgG titer between acute- and convalescent-phase sera (Corsaro and Greub, 2006). Such 641 
recommendations should also be applied to detect a Simkania infection in order to enable 642 
inter-laboratories comparison of obtained results. Alternatively, an ELISA assay 643 
developed in our laboratory to detect W. chondrophila (Lienard et al., 2014) could be 644 
adapted for Simkania infections. Such ELISA might be a good alternative, as the results 645 
are not biased by subjective analysis. Nevertheless, we do not recommend using the assay 646 
developed by Lieberman et al. (Lieberman et al., 1997) since it has not been properly 647 
validated and may overestimate true seroprevalence. 648 
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TREATMENT AND PREVENTION  649 
Antibiotic susceptibility 650 
So far, Simkania infections have been treated empirically with macrolides, similarly to 651 
other Chlamydia infections. Pneumonia was indeed successfully treated with a regimen 652 
of erythromycin (Lieberman et al., 1997). However, in vitro experiments evaluating 653 
antibiotic susceptibility are lacking. Long-term in vitro treatment (4 months) with either 654 
rifampicin or azithromycin was shown to eliminate infectivity; however, DNA was still 655 
detectable and reactivation of the infection was possible with trypsin treatment after 656 
exposure to rifampicin (Kahane et al., 2007a). A treatment by doxycycline might 657 
alternatively be proposed for Simkania spp. infections based on the fact that it is one of 658 
the recommended treatment of Chlamydia and Chlamydia-related infections (de Barsy et 659 
al., 2014; Goy and Greub, 2009; Hammerschlag and Kohlhoff, 2012; Vouga et al., 2015). 660 
Similarly to P. acanthamoebae and N. hartmannellae (de Barsy et al., 2014; Vouga et al., 661 
2015), S. negevensis is resistant to quinolones (Casson and Greub, 2006). This resistance 662 
is probably due to a mutation in two quinolones resistance-determining regions (QRDR) 663 
as shown by genomic analysis, namely in the QRDR of GyrA and ParC, respectively 664 
(Casson and Greub, 2006; de Barsy et al., 2014). Studies reported a resistant phenotype to 665 
β-lactams derivatives (Kahane et al., 1993). However, high concentrations of β-lactams 666 
induce the development of aberrant bodies in W. chondrophila (Jacquier et al., 2014), 667 
despite the fact that it is traditionally considered resistant to β-lactams (de Barsy et al., 668 
2014). The recent discovery of peptidoglycan among Chlamydiales may explain this 669 
finding (Jacquier et al., 2015). A similar phenotype might be observed upon exposure of 670 
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S. negevensis to high dose of β-lactams and might induce a partial bacteriostatic effect 671 
despite apparent resistance at lower concentrations. 672 
 673 
FUTURE CHALLENGES AND CONCLUSIONS 674 
Simkania negevensis, an emerging pathogen? 675 
So far the pathogenic role of S. negevensis is difficult to hammer out, due to the lack of 676 
standardized studies. Although a high serological prevalence was often observed, direct 677 
detection of the pathogen or evidence of acute infections was rare. These findings are 678 
similar to what is observed for C. pneumoniae, whose pathogenic role is nevertheless 679 
commonly accepted. Recent studies reported a prevalence of C. pneumoniae infection of 680 
<2% in patients suffering from community acquired pneumonia (Dumke et al., 2015; 681 
Pletz et al., 2011; Senn et al., 2011; Wellinghausen et al., 2006). In addition, the 682 
correlation between serology and direct identification of C. pneumoniae through PCR is 683 
not good (Wellinghausen et al., 2006) and might be explained by a delay (2-3 weeks) in 684 
the apparition of IgM (Kuo et al., 1995). Thus, recent studies evaluating the role of S. 685 
negevensis infection in pneumonia using MIF might have missed some of the cases. 686 
Therefore, an implication of Simkania in respiratory diseases, especially in children and 687 
young adults, cannot be ruled out and requires further investigations. Despite the 688 
questionable reliability of some of the older studies that did not include controls, cases of 689 
Simkania infection were identified even in recent studies, either as the only putative 690 
pathogen or with other organisms (Dumke et al., 2015; Fasoli et al., 2008; Heiskanen-691 
Kosma et al., 2008; Nascimento-Carvalho et al., 2009). The identification of a few 692 
patients with either a specific Simkania-associated pneumonia or bronchiolitis suggests 693 
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that it might be effectively a true pathogen and might be problematic in endemic regions. 694 
Table 5 summarizes the clinical findings of these patients. Physicians practicing in such 695 
regions, especially in Middle-east, should be aware of the existence of Simkania. In 696 
addition, infection might be promoted in cases of reduction of host defenses, either by a 697 
co-infection or by reduction of the mucociliary function. No information on the 698 
prevalence of Simkania infection in hospitalized patient is available, but, similarly to C. 699 
pneumoniae (Steinhoff et al., 1996), the prevalence might be higher due to increased 700 
proportion of immunocompromised patients. 701 
 702 
Since other members of the Chlamydiales order including C. trachomatis and W. 703 
chondrophila have been associated with miscarriages (Baud et al., 2011b, 2007), a 704 
possible association of S. negevensis with adverse pregnancy outcomes should be 705 
investigated. In addition, pregnancy represents an immunotolerant state where S. 706 
negevensis could find an opportunity to reactivate (Alijotas-Reig et al., 2014; Kropf et al., 707 
2007).  708 
 709 
Simkaniaceae, toward a better comprehension of the Chlamydiales 710 
S. negevensis harbors specificities not present in other Chlamydiales, notably, (i) the 711 
existence of a conjugative plasmid, which could promote genetic variations in this strict 712 
intracellular bacterium and (ii) a type-I intron suggesting a common evolutionary history 713 
with amoebae and/or plant plastids. In addition, the distinct features of S. negevensis 714 
membrane and the specificities of its metabolic pathways could help understanding the 715 
biology and evolution of this fascinating order.  716 
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 717 
In conclusion, S. negevensis represents a Chlamydia-related bacterium of high interest as 718 
it provides new insights into the biology and evolution of the Chlamydiales order. An 719 
implication in human diseases, particularly in respiratory tract infections in children and 720 
young adults, is suspected. Clinicians should thus consider S. negevensis in the 721 
differential diagnosis of respiratory tract infections and should search this pathogen using 722 
a pan-Chlamydiales PCR (Lienard et al., 2011a) or using another specific molecular test, 723 
that will be available in the near future. We recommend an antibiotic treatment with 724 
macrolides based on previous empirical observations, but doxycycline might represent a 725 
good alternative. 726 
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SEARCH STRATEGY AND SELECTION CRITERIA  727 
We searched PubMed for articles published from January 1st, 1990 to September 30th, 728 
2015 with the term “Simkania*” to identify both “Simkania” and “Simkaniaceae” and 729 
identified 81 published articles. We did not search for articles older than this date range 730 
as the first report describing Simkaniaceae was published in May 1993. We also reviewed 731 
relevant references cited in these articles, as well as articles referring to the 732 
“microorganism Z”, which was the first name of S. negevensis. In addition, we searched 733 
the NCBI nucleotide database with the terms “Simkania” and “Simkaniaceae” to recover 734 
potential related sequences.  735 
 736 
737 
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SUMMARY POINTS 738 
1. Simkania negevensis is a novel Chlamydia-related bacterium and the founding 739 
member of the Simkaniaceae family within the Chlamydiales order.  740 
2. S. negevensis is able to replicate within a wide range of hosts including amoebae, 741 
arthropods, mammalian cells and reptiles. 742 
3. Potential virulence factors include the presence of a conjugative plasmid, as well 743 
as a type 3 and a type 4 secretion systems. Pathogenesis may include the ability to 744 
induce persistent latent infections. 745 
4. S. negevensis possess a type I intron in the 23S rRNA encoding gene suggesting a 746 
common evolutionary history with amoebae and/or plant plastids. 747 
5. Evidence of human exposition has been described worldwide. Transmission may 748 
occur through contaminated water. 749 
6. S. negevensis might represent an emerging pathogen associated with bronchiolitis 750 
and pneumonia in children and young adults.  751 
7. Current diagnosis methods comprise PCR, culture with Vero cells or amoebae and 752 
serological assays. 753 
8. Macrolides are the treatment of choice. Quinolones should be avoided, as S. 754 
negevensis is naturally resistant. Caution should be made when using penicillin as 755 
it may induce a persistent stage. 756 
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TABLES AND FIGURE 1304 
Table 1: General features of Simkania negevensis compared to other Chlamydiales 1305 
members  1306 
Table 1 highlights various biological similarities and differences of S. negevensis and 1307 
other Chlamydiales.  1308 
Abbreviations: CPAF, Chlamydia Protease-like Activity Factor; MOMP, Major Outer 1309 
Membrane Protein; n.a., not applicable; nt, Nucleotides; PG, Peptidoglycan; Pmp, 1310 
Polymorphic membrane protein; T3SS, Type 3 Secretion System ; T4SS, Type 4 1311 
Secretion System 1312 
1 (Collingro et al., 2011) 1313 
2 (Carlson et al., 2008; Stephens et al., 1998) 1314 
3 (Bertelli et al., 2010) 1315 
4 (Horn et al., 2004) 1316 
5 (Bertelli et al., 2010; Carlson et al., 2008; Collingro et al., 2011; Horn et al., 2004; 1317 
Stephens et al., 1998) 1318 
6 (Birkelund et al., 2009; Frandi et al., 2014; Jacquier et al., 2014; Kebbi-Beghdadi et al., 1319 
2015; Liechti et al., 2014; Pilhofer et al., 2014, 2013) 1320 
7 (Collingro et al., 2011; Rusconi and Greub, 2013) 1321 
8 (Bertelli et al., 2010; Carlson et al., 2006; Collingro et al., 2011; Horn et al., 2004; Knab 1322 
et al., 2011; Omsland et al., 2014) 1323 
9 Two of them are considered as homologous of OmpA 1324 
10 Strain 2032/99 does not have a plasmid 1325 
11 Putative Pmp encoded in the genome, but not isolated at the membrane 1326 
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12 Putative Pom encoded in the genome, but not isolated at the membrane 1327 
13 One homologue encoded in the genome, but not isolated at the membrane 1328 
 1329 
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1330 
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Table 2: Prevalence of an acute Simkania infection in patients suffering from 1331 
bronchiolitis  1332 
Abbreviations: PCR, Polymerase Chain Reaction; NS, not significant 1333 
		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
Country,	
patients	
Diagnostic	
method	
	
Patients	(%)	
	
Controls	(%)	 p	values	
	
Co-infections	(%)	 Reference	
		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Israel,	239	 PCR	
	
60/239	
	
(25)	
	
0/78	
	
(0)	 <0.001	
	
22/60	
	
(36)	 Kahane,	1998	
	
Immunoperox
idase	
	
14/92	
	
(15)	
	
1/78	
	
(1)	 <0.001	
	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Inuit	
Canada,	22	 PCR		
	
14/22	
	
(63)	
	 	 	 	 	 	
12/14	
	
(85)	 Greenberg,	2003	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	USA,	66	 PCR		
	
9/55	
	
(16)	
	
2/28	
	
(7)	 NS	
	 	 	 	
Kumar,	2005	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	UK,	222	 Nested	PCR	
	
100/222	
	
(45)	
	 	 	 	 	 	 	 	 	
Friedman,	2006	
		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
		 		 		 		 		 		 		 		 		 		 		 		 		 		 		 		
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 1334 
1335 
   
56 
 
 1336 
Table 3: Prevalence of an acute Simkania infection in patients suffering from pneumonia  1337 
Abbreviations: ELISA, enzyme-linked immunosorbent assay; MIA, membrane immune-1338 
assay; MIF, Micro Immunofluorescence; NS, not significant; PCR, Polymerase chain 1339 
reaction  1340 
1 High signal for IgA (> 1.2 OD) or an increase of 0.5 OD units between paired sera 1341 
levels for IgA (1:30) or IgG (1:100) 1342 
2 IgM  ≥ 1:10 or a 4-fold increase between paired sera 1343 
3 When adjusted for recommended IgM cut-off titers ≥ 1:32, results are 12/174 1344 
4 After adjustment 4 1345 
5 IgA ≥ 1:8 1346 
6 pan-Chlamydiales PCR results are only specific at the family-level lineage. These cases 1347 
should therefore be considered as Simkaniaceae infections.” 1348 
 1349 
1350 
   
57 
 
Table 4: PCRs used to detect Simkania in clinical and environmental samples 1351 
1 Amplicon length varies according to Chlamydiales species 1352 
1353 
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Table 5: Patients with Simkania-caused pneumonia 1354 
Abbreviations: CRP, C-reactive protein; id., indeterminate; FMF, familial Mediterranean 1355 
fever; d., days; m.o., months old; PCT, procalcitonin; WBC, white blood cells; y.o., years 1356 
old  1357 
1 WBC > 11'000 is considered significant for a serious bacterial infection 1358 
2 CRP >0.5mg/l is considered significant for a serious bacterial infection 1359 
3 PCT >0.5 microg/l is considered significant for a serious bacterial infection 1360 
1361 
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 1362 
 1363 
1364 
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Figure 1: Evolutionary relationships of Simkaniaceae  1365 
The evolutionary history was inferred using the Neighbor-Joining method (Saitou and 1366 
Nei, 1987) based on 1548 nucleotides from 15 16S rRNA sequences. Sequences were 1367 
retrieved from the NCBI database using “Simkania*” as a research word. The percentage 1368 
of replicate trees, in which the associated taxa clustered together in the bootstrap test (100 1369 
replicates) are shown next to the branches (Efron et al., 1996). The evolutionary distances 1370 
were computed using the Tamura 3-parameter method (Tamura, 1992) and are shown as 1371 
number of base substitutions per site. The rate variation among sites was modelled with a 1372 
gamma distribution. Evolutionary analyses were conducted in MEGA5 after sequence 1373 
analysis on Geneious 7.1.7 (Kearse et al., 2012) 1374 
 1375 
1376 
   
61 
 
SUPPLEMENTARY MATERIALS 1377 
Supplementary table: Clinical studies with Simkania  1378 
Abbreviations: CAP, Community acquired pneumonia; COPD, Chronic obstructive 1379 
pulmonary disease; ELISA, enzyme-linked immunosorbent assay; MIA, membrane 1380 
immune-assay; MIF, Micro Immunofluorescence; NS, Not significant; PCR, Polymerase 1381 
chain reaction; qPCR, quantitative PCR; RTI, Respiratory tract infection 1382 
 1383 
1 Past infections determined by IgG levels 1384 
2 Recent infections determined by high IgM levels, augmentation of IgG or IgM levels 1385 
between two paired sera or PCR 1386 
3 IgG ≥ 1:16 1387 
4 IgG ≥ 1:8, IgM ≥1:10 1388 
5 51 broncho-alveolar lavages and concomitant biopsies obtained from 19 patients 1389 
included 1390 
6 When adjusted for recommended IgM cut-off titers ≥ 1:32, results are 12/174 1391 
7 After adjustment 8/12 1392 
8 Only a 4-fold increase or decrease between paired sera was considerer as positive  1393 
9  IgG ≥ 1:16, IgA ≥1:8 1394 
1395 
   
62 
 
 1396 
 1397 
